WilmerHale Advises ImmPACT Bio On $111 Million Series B Financing

WilmerHale Advises ImmPACT Bio On $111 Million Series B Financing

Firm News

Related Solutions

Helping clients launch their businesses and transform their innovative ideas into successful companies.
WilmerHale has played a leading role in shaping the rules that govern the US financial services industry.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

WilmerHale represented ImmPACT Bio, a clinical-stage company developing transformative logic-gate based chimeric antigen receptor (CAR) T-cell therapies for treating cancer, in its January 2022 $111 million Series B financing.

The financing included co-leads Foresite Capital and Decheng Capital, in addition to Surveyor Capital (a Citadel company). Other investors include the company’s existing investors OrbiMed, Novartis Venture Fund, RM Global Partners (RMGP) and Bukwang Pharmaceutical. The financing proceeds will be used to advance the company’s pipeline of transformative next-generation CAR T-cell therapies that harness the immune system and address key challenges for current cell therapies in cancer.

The WilmerHale team representing ImmPACT Bio included Eric Hanson, Jason Kropp, Victoria Peluso, Naré Aleksanyan and Shaina Hourizadeh.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel